Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 11/20 | 0.41 |
| ▸ | UBE2M | P61081 | 10/20 | 0.41 |
| ▸ | TEAD1 | P28347 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MLNR | O43193 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21958241 | 0.84 | TEAD1 (0.50) | DCUN1D1UBE2MTEAD1KDM4E | |
| SCHEMBL24781297 | 0.81 | KDM4E (0.46) | DCUN1D1UBE2MALDH1A1KDM4EMEN1 | |
| SCHEMBL24781071 | 0.75 | TEAD1 (0.45) | DCUN1D1UBE2MTEAD1MEN1KMT2A | |
| SCHEMBL21958167 | 0.69 | TEAD1 (0.54) | DCUN1D1UBE2MTEAD1MEN1KMT2A | |
| SCHEMBL24780795 | 0.68 | GRIN2B (0.38) | DCUN1D1TEAD1MEN1KMT2A | |
| SCHEMBL21958713 | 0.68 | EGFR (0.66) | DCUN1D1TEAD1KMT2A | |
| SCHEMBL24781284 | 0.66 | SLC6A9 (0.52) | DCUN1D1TEAD1MEN1KMT2A | |
| SCHEMBL23592000 | 0.66 | TEAD1 (0.48) | DCUN1D1UBE2MTEAD1 | |
| SCHEMBL24780804 | 0.66 | TEAD1 (0.48) | DCUN1D1UBE2MTEAD1 | |
| SCHEMBL24781682 | 0.65 | EPHX2 (0.60) | DCUN1D1UBE2MMEN1KMT2AMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | DCUN1D1 1458/4885UBE2M 1903/4885TEAD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.